New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration

الملخص EN

Age-related macular degeneration (AMD) is the leading cause of visual loss in older population.

Angiogenesis is an important factor associated with the development of CNV due to AMD.

Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care.

However, not all patients respond to monotherapy, and modified anti-VEGF treatment regimen and combination therapy may target reducing treatment frequency or improving visual outcome.

This paper reviews the many clinical trials that have been performed utilizing several treatment regimens.

While many trials have shown that this variable therapy is justifiable, further study is required to determine correct regimens and dosage.